How muscle-targeting RNA vaccines work against viruses
Official title: Immunological mechanism of muscle-localizing self-replicating RNA vaccines
Funded at Hdt Bio Corporation · NIH-10781834 · Data updated 2026-11-12
This study is testing a new kind of RNA vaccine designed to help your body fight off viral infections like COVID-19 by boosting your immune response, and it’s looking for participants to see how well it works and if it’s safe.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Hdt Bio Corporation NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | September 13, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $1,074,519 |
| NIH project number | 1R01AI180195-01 |
| Project ID | NIH-10781834 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation would include individuals at risk for viral infections, particularly those vulnerable to COVID-19 and other respiratory viruses.
✕Less likely to help
Patients who are not at risk for viral infections or those who have contraindications to RNA vaccines may not benefit from this research.
What this research studies
This research investigates a new type of RNA vaccine that targets muscle cells to improve immune responses against viral infections, including COVID-19. By using self-replicating RNA delivered through specialized carriers, the vaccine aims to enhance the body's ability to produce antibodies and T cells while minimizing side effects. The study focuses on understanding how these vaccines can effectively stimulate the immune system without causing unwanted reactions. Patients may be involved in trials to assess the safety and efficacy of this innovative vaccination approach.
Why it matters
Potential benefit: If successful, this research could lead to more effective vaccines that provide better protection against viral infections with fewer side effects.
How similar studies have gone: Previous research has shown promise in using RNA vaccines for viral infections, but this specific approach with muscle-localizing self-replicating RNA is relatively novel.
Where this research is happening
-
Hdt Bio Corporation
Seattle, United States Active
Researchers
- Principal investigator: Kimura, Taishi — Hdt Bio Corporation
- Study coordinator: Kimura, Taishi
Related research
Other NIH-funded projects on the same topics.
-
How muscle-targeted self-replicating RNA vaccines trigger immunity
This project looks at how self-amplifying RNA vaccines delivered to muscle activate immune responses to protect people from respiratory viruses like COVID-19, RSV, and influenza.
-
Developing an RNA vaccine to enhance the immune response against HIV
This study is testing a new mRNA vaccine that aims to help your immune system fight HIV-1 by encouraging it to produce strong antibodies, using a special delivery method to make it work better.
-
Innovative RNA vaccines for tuberculosis targeting the mucosal immune system
This study is working on a new RNA vaccine to help boost the immune system's fight against tuberculosis, especially in the lungs, and it's designed to be both effective and affordable for people who need it.
-
Developing treatments for enteroviruses affecting children
This study is working on developing special antibodies to help fight off enteroviruses like EV-D68, which can make young children very sick, and aims to create new treatments since there aren’t any available right now.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.